Drug Profile


Alternative Names: ILY-105; Patiromer calcium; Patiromer for Oral Suspension; Patiromer FOS; Patiromer sorbitex calcium; RLY-105; RLY-5016; RLY-5016S; RLY5016 for Oral Suspension; Veltassa

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Relypsa
  • Developer Relypsa; Vifor Fresenius Medical Care Renal Pharma
  • Class Polymers
  • Mechanism of Action Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperkalaemia

Most Recent Events

  • 09 Jan 2017 Relypsa initiates the phase II AMBER trial for Hyperkalaemia in Hungary (PO) (EudraCT2016-002657-38)
  • 28 Nov 2016 US FDA approves sNDA application for patiromer by removing boxed warning regarding drug-drug interactions
  • 02 Sep 2016 Relypsa has been acquired by Vifor Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top